Nivolumab and TACE (N=31) | ||||
Grade 1 n (%) | Grade 2 n (%) | Grade 3–4 n (%) | Grade 5 n (%) | |
Immunotherapy attributed | ||||
Dermatological | 5 (16) | 2 (6.5) | 1 (3.2) | – |
Diarrhea/colitis | 2 (6.5) | 1 (3.2) | – | – |
Fatigue | 4 (13) | 1 (3.2) | – | – |
Liver toxicity | – | 4 (13) | – | – |
Thyroid toxicity | 1 (3.2) | 3 (9.7) | – | – |
Polyarthritis | – | – | 1 (3.2) | – |
Pneumonitis | – | – | – | – |
Anorexia/weight loss | 1 (3.2) | 2 (6.5) | – | – |
Fever | 1 (3.2) | 1 (3.2) | – | – |
Pruritus | 1 (3.2) | 1 (3.2) | – | – |
Other toxicities | 3 (9.7)* | 2 (6.5)† | 1 (3.2)‡ | – |
TACE attributed | ||||
Abdominal pain | 10 (32) | 1 (3.2) | – | – |
Fever | 2 (6.5) | – | – | – |
Fatigue | 3 (9.7) | – | – | – |
Transaminitis | 1 (3.2) | 2 (6.5) | – | – |
Nausea/vomiting | 2 (6.5) | – | – | – |
Nivolumab alone (N=104) | ||||
Grade 1 n (%) | Grade 2 n (%) | Grades 3 and 4 n (%) | Grade 5 n (%) | |
Dermatological | 15 (14) | 5 (4.8) | 2 (1.9) | – |
Diarrhea/colitis | 4 (3.8) | – | 1 (1.0) | – |
Fatigue | 13 (13) | 2 (1.9) | – | – |
Liver toxicity | 9 (8.7) | – | – | – |
Thyroid toxicity | 4 (3.8) | – | – | – |
Polyarthritis | 1 (1.0) | – | 1 (1.0) | – |
Pneumonitis | 1 (1.0) | 2 (1.9) | – | – |
Anorexia/weight loss | 1 (1.0) | – | 1 (1.0) | – |
Fever | – | 2 (1.9) | – | – |
Pruritus | – | – | – | – |
Other toxicities | 4 (3.8)§ | 3 (2.9)¶ | 1 (1.0)** | 1 (1.0)†† |
*Balanitis, hair loss, infusion reaction.
†Epigastric pain, nephritis.
‡Shortness of breath
§Pituitary, double vision, anemia, constipation
¶Hepatic coma, visual changes and constipation
**Amylase/lipase
††Myocarditis
TACE, transarterial chemoembolization.